Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is known of either the normal or the pathological role of LRRK2. We have created lines of mice that express human wild-type (hWT) or G2019S Lrrk2 via bacterial artificial chromosome (BAC) transgenesis. In vivo analysis of the dopaminergic system revealed abnormal dopamine neurotransmission in both hWT and G2019S transgenic mice evidenced by a decrease in extra-cellular dopamine levels, which was detected without pharmacological manipulation. Immunopathological analysis revealed changes in localization and increased phosphorylation of microtubule binding protein tau in G2019S mice. Quantitative biochemical analysis confirmed the presence of differential phospho-tau species in G2019S mice but surprisingly, upon dephosphorylation the tau isoform banding pattern in G2019S mice remained altered. This suggests that other post-translational modifications of tau occur in G2019S mice. We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation. Our models will be useful for further understanding of the mechanistic actions of LRRK2 and future therapeutic screening.
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Introduction
LRRK2 mutations represent a unique opportunity for the development of genetic model systems for Parkinson's disease (PD). LRRK2 mutations are the most common form of familial parkinsonism and account for up to 40% of sporadic parkinsonism in certain populations (reviewed by Farrer, 2006) . Clinically and pathologically, the features of LRRK2-associated parkinsonism are often indistinguishable from idiopathic PD; although pathologic variability exists even within PARK8-linked kindreds, ranging from nigral neuronal loss only, to neuronal loss with α-synuclein, ubiquitin or tau inclusions (reviewed by Whaley et al., 2006) . To date, four different domains (ROC, Cterminal of ROC, kinase and WD40) of Lrrk2 are known to be affected by mutation/risk factors. While the ultimate downstream consequence of LRRK2 mutation in humans is parkinsonism, it is still unclear if the variants share common pathogenic mechanisms or if individual variants exert specific effects.
Until recently, hypotheses about Lrrk2 dysfunction were based on data from lower model organisms and cellular systems. Several lines of evidence now point towards an important role of Lrrk2 in neuronal outgrowth and guidance (MacLeod et al., 2006; Plowey et al., 2008; Sakaguchi-Nakashima et al., 2007; van Egmond et al., 2008) . Mechanistic studies have repeatedly observed increased kinase activity for the most common G2019S mutation, however the mode of action for the other mutations has remained conflicting (Greggio and Cookson, 2009) . With the emergence of several rodent mutant LRRK2 models, in vivo insight into the mechanistic actions is now forthcoming. ROC domain mutant human R1441G bacterial artificial chromosome (BAC) and R1441C knock-in mice both exhibit impaired 
